Archives by Month:
- November 2024
- October 2024
- September 2024
- August 2024
- July 2024
- June 2024
- May 2024
- April 2024
- March 2024
- January 2024
- December 2023
- November 2023
- October 2023
- August 2023
- July 2023
- June 2023
- May 2023
- February 2023
- January 2023
- December 2022
- November 2022
- October 2022
- September 2022
- August 2022
- July 2022
- June 2022
- May 2022
- April 2022
- March 2022
- February 2022
- January 2022
- December 2021
- November 2021
- October 2021
- September 2021
- August 2021
- July 2021
- June 2021
- May 2021
- April 2021
- March 2021
- February 2021
- January 2021
- December 2020
- November 2020
- October 2020
- September 2020
- August 2020
- July 2020
- June 2020
- May 2020
- April 2020
- March 2020
- February 2020
- January 2020
- December 2019
- December 2018
- November 2018
- October 2018
- September 2018
- August 2018
- July 2018
- June 2018
- May 2018
- April 2018
- March 2018
- February 2018
- January 2018
- December 2017
- November 2017
- October 2017
- September 2017
- August 2017
- July 2017
- June 2017
- May 2017
- April 2017
- March 2017
- February 2017
- January 2017
- December 2016
- November 2016
- October 2016
- September 2016
- July 2016
- June 2016
- April 2016
- March 2016
- February 2016
- January 2016
- December 2015
- November 2015
- October 2015
- September 2015
- August 2015
- July 2015
- June 2015
- May 2015
- April 2015
- March 2015
- February 2015
- January 2015
- December 2014
- November 2014
- October 2014
- September 2014
- August 2014
- July 2014
- June 2014
- May 2014
- April 2014
- March 2014
- February 2014
- January 2014
- December 2013
- November 2013
- October 2013
- September 2013
- August 2013
- July 2013
- June 2013
- May 2013
- April 2013
- March 2013
- February 2013
- January 2013
- November 2012
- October 2012
- August 2012
- July 2012
- June 2012
- May 2012
- April 2012
- March 2012
- February 2012
- January 2012
- December 2011
- November 2011
- October 2011
- September 2011
- August 2011
- July 2011
- June 2011
- May 2011
- April 2011
- March 2011
- February 2011
- January 2011
- December 2010
- November 2010
- October 2010
- September 2010
- August 2010
- July 2010
- June 2010
- May 2010
- April 2010
- March 2010
- February 2010
- January 2010
- December 2009
- November 2009
- October 2009
- September 2009
- August 2009
- June 2009
- April 2009
- February 2009
- December 2008
- November 2008
- October 2008
- August 2008
- June 2008
- May 2008
Archives by Year:
Teva Rallies After Finding Experienced CEO, But Not Astra’s, To Take Over
Shares of Teva Pharmaceutical (TEVA) surged in morning trading after naming a permanent chief executive officer, ending a monthlslong search for a new chief. The new CEO brings 30 years of global pharmaceutical and healthcare experience. CEO APPOINTMENT: Teva this morning said that it has named named Kare Schultz to be its new president and […]
We Didn’t Start The Fire
What should long-duration common stock owners like us do with the news of the horrific flood in Texas, the Category 5 hurricane in the Caribbean, the heightened tensions created by North Korea’s Dictator, Kim Jong-un, and the 8.1 magnitude earthquake in Southern Mexico? What is wise behavior in a more volatile stock market environment created […]
Are CTAs Behind The Bond Rally
Well, anyone who was frustrated with 10Y yields closing in on a 1 handle is likely a little less irritated on Monday. The broad risk-on move now has yields up some 7bps on 10s, although in the grand scheme of things, 2.12 and change probably isn’t what everyone had in mind in January when “short […]
S&P’s Irma-Relief Rally Erases “Fire & Fury” Losses
“Fire & Fury”, Gary Cohn concerns, North Korean missiles over Japan, Hurricane Harvey, North Korean Hydrogen Bomb tests, and now Hurricane Irma… and stocks are higher… As Bob Pisani said “it just does not want to go down”.
Three Massive Bubbles In 17 Years: When Will This One Bust? A 60% Decline Coming?
John Hussman’s presents a message no one wants to hear because nearly everyone is too busy believing for the third time in 17 years that “It’s different this time”. Last week Hussman wrote about Valuations, Sufficient Statistics, and Breathtaking Risks. This week it’s more of the same with his post Behind the Potemkin Village. The markets are […]
AUDUSD Daily Analysis – Monday, Sept. 11
AUDUSD remains in the uptrend from 0.7807, the fall from 0.8124 is likely consolidation of the uptrend. Near-term support is located at the bullish trend line on the 4-hour chart. As long as the price is above the trend line, the upside movement could be expected to continue and next target would be at 0.8162. On […]
Irma Aftermath Puts These ETF Areas In Focus
The effect of the highly talked-about Hurricane Irma was weaker than feared in Florida but the level of destruction was still pretty high. The cost of the storm varies from analyst to analyst. As per the guardian, “the economic cost of Hurricane Irma could rise as high as $300 billion” as it ravaged homes, businesses and […]
Jefferies Says Cryptocurrency Not A Fad, Sees No Imminent Risk For Nvidia, AMD
While commenting on cryptocurrency exposure at both Nvidia (NVDA) and AMD (AMD), Jefferies analyst Mark Lipacis argued that the risk of a “crypo-driven” inventory correction driving material downside is low in the near-term. CRYPTOCURRENCIES NOT ‘A FAD’: In a research note this morning, Jefferies’ Lipacis told investors that he estimates cryptocurrency revenues accounted for about […]
Middle-Class Chinese Say A $1,000 IPhone Is “Too Expensive”
Apple Inc. had hoped that its iPhone eight might demolish the company’s sales records in China as the country’s burgeoning middle class embraced the phone, thanks in part to its name: Eight is considered a lucky number in Chinese culture, signifying wealth and fortune. Unfortunately for the world’s most valuable company, this calculus isn’t playing […]
5 Top-Ranked Biotech Stocks To Buy Right Now
Biotech stocks are back in favor thanks to two recent major developments that led to a rally in the sector. The first catalyst was Gilead Sciences’ (GILD – Free Report) announcement that it will be acquiring immunotherapy focused company, Kite Pharma (KITE – Free Report) while the FDA approval of the first gene therapy in the United States, Novartis […]
